专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015148825A3 METHODS AND COMPOSITIONS FOR EVALUATING BREAST CANCER PATIENTS 审中-公开
标题翻译：用于评估乳腺癌患者的方法和组合物
公开(公告)号：WO2015148825A3
公开(公告)日：2015-11-19
申请号：PCT/US2015022788
申请日：2015-03-26
申请人： LI RONG , YUAN BIN , YE QINONG , CHENG LONG
发明人： LI RONG , YUAN BIN , YE QINONG , CHENG LONG
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , C07K16/2869 , C07K2317/30 , G01N2800/52
摘要： Embodiments are directed to methods of evaluating the prognosis of a breast cancer patient by assessing the level of phosphorylation tyrosine 36 of estrogen receptor beta (ERB). Certain embodiments are directed to methods for evaluating the prognosis of a cancer patient comprising contacting a breast cancer sample from a patient with stage II or stage III breast cancer with an antibody that binds phosphorylated tyrosine 36 of Εί¾β; quantifying phosphorylation of tyrosine 36 of ΕΙ¾β; and classifying the patient as having a good prognosis if phosphorylated tyrosine 36 levels are elevated or classifying the patient as having a poor prognosis if tyrosine levels are decreased relative to a non-cancer control. Certain embodiments are directed to an antibody or antibodies that specifically bind tyrosine 36 (Y36) of the ERp.
摘要翻译：实施方案涉及通过评估雌激素受体β（ERB）的磷酸化酪氨酸36的水平来评估乳腺癌患者的预后的方法。某些实施方案涉及用于评估癌症患者的预后的方法，包括使患有II期或III期乳腺癌的患者的乳腺癌样品与结合磷酸化酪氨酸36的抗体接触; 定量Ε3/4β酪氨酸36的磷酸化; 并且如果如果酪氨酸水平相对于非癌症对照降低，如果磷酸化酪氨酸36水平升高或将患者分类为具有差的预后，则将患者分类为具有良好的预后。某些实施方案涉及特异性结合ERp的酪氨酸36（Y36）的抗体或抗体。

IPRDB

热门服务

关于我们

友情链接

联系方式